Revisit: BIO on the American Road stopped in Research Triangle Park (RTP) on Oct. 2nd - #MFGDay26! BIO President & CEO John F. Crowley led a delegation that, alongside @NCLifeSci , toured @ncbiotech and @Biogen's RTC campus with Rep. @DeborahRossNC (D-NC), meeting with local industry leaders and patient advocates. Read more on Bio.News: bio.news/state-policy/bio-on…
From the boardroom to the news media, veteran healthcare broadcast journalist @MikeHuckman, Principal of The Huckman Group, will lead an interactive #BIOPACE26 workshop helping patient advocates and industry leaders deliver concise, clear, confident and quotable messages. Learn more about the program: pace.bio.org
Patients living with rare disease often cannot be served by traditional drug development paradigms. Today, BIO applauds the FDA for the launch of the Rare Disease Framework Initiative to develop a fit-for-purpose framework for rare disease drug development.
In 2024, Marci Pedrazzi McCue became the first person in a U.S. clinical trial to receive an investigational CAR-T cell therapy for MS. For Marci, the courage to try something new brought hope for a future with greater certainty and independence.
Her journey reflects the work of Dr. Jeffrey Dunn and the Stanford University School of Medicine team, Dr. Naji Gehchan and @kyverna_us, and the countless others pushing science forward for everyone living with MS.
This is Marci's story: fightofourlives.com/stories/…
#FightofOurLives #MultipleSclerosis #Biotechnology
SBIR and STTR, the federal seed funding programs Congress reauthorized in March, now offer larger awards and new paths for biotech start-ups. What should applicants know before the Jan. 5 deadline? Bio.News has NCI's guidance: bio.news/federal-policy/nati…
Small and emerging biotechs drive the innovation patients depend on, often investing years in research and development before a treatment ever reaches a patient. That progress relies on the ability to sustain investment through years of clinical trials, uncertainty and setbacks.
Importing other countries’ price controls risks undermining that investment and jeopardizing future treatments - without addressing the role insurers and middlemen play in driving up medicine costs.
It’s time to #SimplifyTheSystem: bio.org/simplify-the-system
Last call for BIO 2027 session submissions! The deadline to submit is this Thursday, Oct. 15. Submitting is free, and accepted proposals come with General Access registration. convention.bio.org/program/2…
Policy is dynamic, complex, and can be challenging to navigate. BIO's upcoming Patient Advocacy Coffee Chat will examine strategic opportunities for patient groups to advance policy priorities that improve patient access to therapies.
Advocacy in Action
Tuesday, October 13 | 12:00–1:00 PM ET
Speakers:
Ellie Dehoney, Senior Vice President of Policy and Advocacy, Research!America
Amanda Krzepicki, MPH, Policy Director, @AutoimmuneAssoc
Brian DuVal, MPH, Director, Patient Advocacy, Biotechnology Innovation Organization (BIO)
Moderated by Karin Hoelzer, DVM, PhD, Senior Director, Patient Advocacy, BIO
Register: bio-org.zoom.us/meeting/regi…
In 2022, Peter and Maggie Dion were diagnosed with limb-girdle muscular dystrophy. There were no trials. Their parents, Joe and Courtney Dion of @DionFund, came to Washington to advocate for the reauthorization of the Pediatric Priority Review Voucher (PPRV) program, and the first trial started in 2025.
BIO's Chief Patient Advocate Michele Oshman joined the Dions for a keynote at the Rare Trials Summit. More from the keynote on Bio.News: bio.news/federal-policy/in-r…
For smaller biotech companies, the new Section 232 tariff is more than an added cost - it adds uncertainty at exactly the wrong time. With tariffs now in effect, companies already operating with limited resources are facing higher costs, scarce capital, and unanswered questions about how to navigate the new rules. For early-stage programs, those pressures can influence critical decisions about what gets advanced - and what doesn’t. More in @statnews: statnews.com/2026/10/08/trum…
Every breakthrough begins with patients willing to go first - determined to turn their own fight into hope for others. In BIO's new Patient Pioneers story, patients and families who have faced acute lymphoblastic leukemia, sickle cell disease, and multiple sclerosis reflect on what it means to be among the first to advance a new frontier in medicine - and to move the #FightOfOurLives forward. Their experiences differ, but they share one belief: progress is only possible when patients and scientists take big steps together.
Among them is Marci Pedrazzi McCue, the first person in a U.S. trial to receive CAR-T cell therapy for MS. As she puts it: "I think that when you're in a mindset of trying anything that's available to stop your disease, you're not afraid to be patient number one."
Their courage moves the fight forward - for every patient still waiting.
Watch their stories: fightofourlives.com/stories/…
CDKL5 deficiency disorder causes severe seizures beginning in infancy, and no approved therapy addresses its underlying biology. BrainStorm Therapeutics, the Seed-Stage Start-Up Stadium winner at #BIO2026, is developing one. Read more: bio.news/bio-convention/brai…
iNFixion Bioscience won a Start-Up Stadium top prize at #BIO2026. Bio.News talks with CEO Herb Sarnoff about the company's work on neurofibromatosis type 1, a rare disease that affects 125,000 Americans. Read more: bio.news/bio-convention/infi…
50 years of biotechnology in 50 seconds 🧬⏱️
Silvia Taylor, Executive Vice President, Chief Corporate Affairs Officer and Head of Novavax Sweden at @Novavax, and Co-Chair of BIO's Trust in Science Task Force, looks ahead to the next 50 years of biotech, as AI and machine learning change the pace of progress across the industry.
#Biotech50
Stop 2 & 3 🚐🧬 -> From patients to production: In the Research Triangle, BIO met with patient advocate leaders over lunch, then joined @RepDeborahRoss, @NCLifeSci, and @ncbiotech at @biogen on 30 years of regional growth powered by industry, government, and academic partnership. #BIOontheAmericanRoad #MFGDay26
BIO on the American Road is kicking off Manufacturing Day (#MFGDay26) in North Carolina's Research Triangle. Thank you to @ncbiotech for hosting this morning's industry roundtable with BIO President and CEO John F. Crowley and @NCLifeSci Laura Gunter. The conversation highlighted the strength and diversity of the state's life sciences ecosystem, where top-tier research universities, a strong talent pipeline, and thriving companies are moving innovation forward. #BIOontheAmericanRoad
What is the Prescription Drug User Fee Act (PDUFA) and why does it matter to patient advocates? #BIOPACE26 will break down #PDUFA VIII in plain language, with a look at where advocates can engage. Learn more: pace.bio.org
BIO's own Steve Berman will be joined by Jeff Allen, President & CEO of @CancerResrch, and Adora Ndu, PharmD, JD, Chief Regulatory Officer, and Executive Vice President of Portfolio Strategy and Management at @BridgeBioPharma.
The future of American biotech depends on all of us pulling in the same direction - for patients, for innovation, for continued U.S. leadership. Congrats to Eric Cantor on being named @PhRMA's next president and CEO, and thank you to Steve Ubl for a decade-plus of committed leadership!
We are excited to announce Eric Cantor as our next president and CEO.
Eric is well respected among policy leaders in Washington and around the world, with a long track record of working effectively across the political spectrum in support of biomedical research and patients’ access to medicines. He joins PhRMA at a pivotal moment for America’s biopharmaceutical industry.
Read more: phrma.org/resources/phrma-se…
